MINNEAPOLIS, Sept. 18, 2007 (PRIME NEWSWIRE) -- Vascular Solutions, Inc. (Nasdaq:VASC) today announced that the Company is scheduled to present at the 2007 UBS Global Life Sciences Conference in New York City on Tuesday, September 25, 2007 at 1:30pm (EST).
Howard Root, Chief Executive Officer of Vascular Solutions, will deliver the Company's presentation. To hear the live audio webcast of the Vascular Solutions' presentation, go to the investor relations page of the Company's web site http://www.vascularsolutions.com and click on the "IR Conferences" icon a few minutes prior to start time to download any necessary software.
About UBS
UBS's Investment Bank is one of the world's leading firms in the investment banking and securities business, providing a full spectrum of services to the world's key institutional investors, intermediaries, banks, insurance companies, corporations, sovereign governments, supranational organizations and private investors. For both its own corporate and institutional clients and the individual clients of other parts of UBS, the Investment Bank provides product innovation, research and advice, and comprehensive access to the world's capital markets.
About Vascular Solutions
Vascular Solutions, Inc. is a medical device company that focuses on developing unique solutions for unmet clinical opportunities within Interventional radiology and Interventional cardiology. New products introduced since the second half of 2003 include the Vari-Lase(r) endovenous laser product line for the treatment of varicose veins, the D-Stat Dry(tm) hemostatic bandage for the rapid control of topical bleeding, the Pronto(tm) extraction catheter for the mechanical extraction of soft thrombus, the Langston(r) dual lumen catheter for the measurement of aortic stenosis and the Twin-Pass(tm) dual access catheter for dual wire access in interventional cardiology procedures. The Company's other major products include the Duett(tm) sealing device to rapidly seal the puncture site following catheterization procedures and the D-Stat(r) Flowable hemostat for the local management of active bleeding.
The information in this press release contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those discussed in our Annual Report on Form 10-K for the year ended December 31, 2006 and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with the need for adoption of our new products, limited working capital, lack of profitability, exposure to intellectual property claims, dependence on key vendors, exposure to possible product liability claims, the development of new products by others, doing business in international markets, limited manufacturing experience, the availability of third party reimbursement, and actions by the FDA.
For further information, connect to www.vascularsolutions.com.